A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504855-28-00

Acronym

MK-4464-001

Enrollment

Registered

2023-06-21

Start date

2023-03-21

Completion date

2025-04-10

Last updated

2025-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced/metastatic solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026